- Title
- Update of FORTITUDE-ALS: A Phase 2, Double-blind, Randomized, Placebo-Controlled, Study to Evaluate Efficacy, Safety and Tolerability of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (S5.002)
- Creators
- Jeremy Shefner - Barrow Neurological InstituteJinsy Andrews - Columbia University Irving Medical CenterAngela Genge - Montreal Neurological Institute and HospitalCarlayne Jackson - The University of Texas at San Antonio Health Science CenterNoah Lechtzin - Johns Hopkins UniversityTimothy Miller - Washington University in St. LouisBettina Cockroft - Cytokinetics (United States)Fady Malik - Cytokinetics (United States)Jenny Wei - Cytokinetics (United States)Andrew Wolff - Cytokinetics (United States)Stacy Rudnicki - Cytokinetics (United States)
- Publication Details
- Neurology, Vol.92(15_supplement)
- Identifiers
- 991006262291502656
- Academic Unit
- Neurology
- Language
- English
- Resource Type
- Journal article
Journal article
Update of FORTITUDE-ALS: A Phase 2, Double-blind, Randomized, Placebo-Controlled, Study to Evaluate Efficacy, Safety and Tolerability of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (S5.002)
Neurology, Vol.92(15_supplement)
04/09/2019
Metrics
1 Record Views